{
  "id": 17865134,
  "title": "Earnings call transcript: Cerus posts Q3 2026 revenue beat as stock falls after hours",
  "url": "https://urgent.news/2026/11/02/earnings-call-transcript-cerus-posts-q3-2026-revenue-beat-as-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T22:23:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-cerus-posts-q3-2026-revenue-beat-as-stock-falls-after-hours-93CH-4993056"
  },
  "original_language": "en",
  "account": "Cerus Corporation reported a revenue of $64 million in Q3 2026, surpassing Wall Street's forecast of $63.25 million. Despite this, the company's stock experienced a 6.78% decline in after-hours trading, settling at $2.20. The increase in product revenue by 10% to $57.7 million contributed to the earnings beat, while adjusted EBITDA remained positive for the 10th consecutive quarter, amounting to $5.7 million. The GAAP net loss narrowed to under $1 million, nearing breakeven. However, Cerus did not disclose an EPS figure, leaving analysts puzzled. The stock initially rose in the regular session but fell after hours, signaling caution from investors. Positive developments included strong business momentum across core franchises, a 12% year-over-year increase in North American product revenue driven by INTERCEPT platelets and growing IFC adoption, and ahead-of-expected INT200 illuminator placements in Europe, the Middle East, and Africa. The company emphasized operating leverage, higher IFC kit sales, and better inventory control. Cerus also shared positive top-line results from its RedeS phase III trial for red blood cell pathogen reduction, which met its primary efficacy endpoint without statistically significant differences in safety outcomes. Revenue growth for the year-to-date period stood at 15%, driven by the blood safety franchise. Gross margin fell slightly to 52.4%, while R&D spending decreased by 10%. The company reaffirmed its full-year 2026 product revenue guidance and expected CE mark clearance for its red cell program in late 2027, later than initially anticipated. Wall Street remains optimistic, with analysts maintaining a Strong Buy consensus and price targets ranging from $4.00 to $6.50.",
  "summary": "Cerus Corporation reported Q3 2026 revenue of $64 million, surpassing Wall Street expectations of $63.25 million. Despite this positive revenue beat, the company's stock fell 6.78% in after-hours trading as investors reacted cautiously. The company's product revenue rose 10% year over year to $57.7 million, contributing to a positive adjusted EBITDA for the 10th consecutive quarter. The net loss narrowed to under $1 million, nearing breakeven, with the company highlighting stronger product mix and better inventory control as key drivers of improved profitability.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}